Novo Nordisk Thailand has signed an MoU with HSRI – and the Health Systems Research Institute – to strengthen Thailand’s clinical research infrastructure and foster healthcare innovation. The agreement, witnessed by Danish Ambassador Danny Annan on 29 May 2025, aims to enhance training, unify research standards, and improve data systems for more efficient drug development.
Dr Supakij Sirilak, Director of HSRI, highlighted the country’s strong hospital network and universal healthcare as key assets, but stressed the need for improved support systems, including personnel training and unified ethics frameworks. Novo Nordisk’s General Manager, Enrico Cañal Bruland, noted the company’s rising R&D investment in Thailand—THB 370 million over 2019–2023—and said the partnership aligns with the global theme of “Leading, Collaborating, Innovating.”
The initiative is expected to boost Thailand’s competitiveness in global clinical trials and deliver long-term benefits to the health system and economy.
Source: Bangkok Post
